Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Profound Medical Corp. is a medical technology company focused on developing and commercializing incision-free therapeutic systems that use magnetic resonance–guided focused ultrasound (MRgFUS). The company operates within the medical devices and image-guided therapy industries, with a primary clinical focus on urology and women’s health. Its core value proposition is enabling precise, non-invasive tissue ablation under real-time MRI guidance, designed to reduce complications and recovery time compared to traditional surgical or radiation-based therapies.
The company’s principal revenue drivers are its TULSA-PRO® System, used for prostate tissue ablation, and the Sonalleve® MR-HIFU System, primarily used for uterine fibroids and palliative pain treatment in bone metastases. Profound Medical was founded in 2008 and is headquartered in Canada. It evolved through early academic research in focused ultrasound, followed by clinical validation, regulatory approvals in the U.S., Canada, and Europe, and a transition toward commercial-scale deployment, particularly in the U.S. prostate cancer and benign prostatic hyperplasia markets.
Business Operations
Profound Medical operates through two primary business lines: the TULSA business segment, centered on the TULSA-PRO platform, and the Sonalleve business segment, which includes systems and consumables originally acquired from Philips. Revenue is generated through capital equipment sales, recurring disposable device sales, service contracts, and, to a lesser extent, licensing and research-related activities. The TULSA segment represents the company’s strategic and commercial priority and accounts for the majority of recent revenue growth.
Operations span North America and Europe, with direct sales in the United States and distributor-based sales in select international markets. The company controls proprietary software, transurethral ultrasound applicators, and MRI-integrated treatment planning technology. Its principal operating subsidiary is Profound Medical USA, Inc., which supports U.S. commercialization, clinical education, and regulatory activities.
Strategic Position & Investments
Profound Medical’s strategy is centered on expanding adoption of TULSA-PRO as a differentiated alternative to surgery and radiation for prostate disease, supported by clinical evidence generation, physician training, and reimbursement progress. Growth initiatives include increasing system placements, expanding indications within prostate care, and driving recurring revenue from disposables and services tied to its installed base.
A key strategic investment was the acquisition of Sonalleve® assets from Philips, which broadened the company’s technology portfolio and intellectual property base in MR-guided focused ultrasound. The company continues to invest in software automation, treatment precision, and workflow integration, positioning itself within the emerging field of non-invasive, image-guided therapeutic platforms. Public disclosures indicate no material diversification outside focused ultrasound–based therapies.
Geographic Footprint
Profound Medical is headquartered in Canada, with its principal executive and administrative offices located in Toronto. The company’s most significant commercial presence is in the United States, which represents its largest market by revenue and strategic focus, supported by its U.S. subsidiary and a growing base of installed systems.
Internationally, the company has market presence across Europe, including Germany, the United Kingdom, and other EU countries, primarily through distribution partners. Its systems are installed across North America and Europe, and the company maintains regulatory clearances that allow for broader international expansion, although commercial activity outside these regions remains limited based on publicly available data.
Leadership & Governance
Profound Medical is led by executives with backgrounds in medical devices, imaging, and focused ultrasound research, emphasizing clinical validation, regulatory discipline, and long-term technology differentiation. Leadership has articulated a strategy focused on evidence-based adoption, physician education, and disciplined capital allocation to support sustainable growth.
Key members of leadership include:
- Arun Menawat – Chief Executive Officer
- Mark R. McDannold – Chief Technology Officer
- Kullervo Hynynen – Founder and Chief Scientific Advisor
The board and executive team combine commercial medical device experience with deep academic roots in MRI-guided focused ultrasound, reflecting the company’s dual emphasis on scientific credibility and market execution.